Toxicity in combined modality treatment of HNSCC: Cisplatin versus cetuximab.
A. Chew
No relevant relationships to disclose
J. Hay
No relevant relationships to disclose
J. J. Laskin
No relevant relationships to disclose
J. Wu
No relevant relationships to disclose
C. Ho
Honoraria - Bristol-Myers Squibb